Schizophrenia – Epidemiology – Epidemiology Dashboard
DRG Epidemiology's coverage of Schizophrenia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of Schizophrenia for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, the number of drug-treatment opportunities at specific lines of therapy are also forecast across the major mature pharmaceutical markets.
DRG Epidemiology's Schizophrenia forecast will answer the following questions:
- How will changes in the levels of exposure to known risk or protective factors affect the number of people living with Schizophrenia?
- Of all people with Schizophrenia, how many people in each country have been formally diagnosed?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of Schizophrenia over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, DRG Epidemiology forecasts Schizophrenia patient populations, as follows:
- Diagnosed incident cases
- Diagnosed lifetime prevalent cases
- Diagnosed lifetime prevalent cases by symptom scheme
- Diagnosed lifetime prevalent cases by cormorbidity scheme
- Diagnosed lifetime prevalent cases by cognitive effect scheme
- Diagnosed drug-treated lifetime prevalent cases
- Lifetime DALYs gained
- … and many more (details available on request).
Table of contents
- Schizophrenia - Epidemiology - Epidemiology Dashboard
- Introduction
- Epidemiology Dashboard
- Introduction
Swarali Tadwalkar, M.P.H., is a principal epidemiologist at Clarivate. Previously, she was involved in primary and secondary healthcare research, including projects in digital health, health policy and management, and health economics and outcomes research (HEOR). Ms. Tadwalkar also coordinated various nongovernmental public health projects focusing on access to treatment for hepatitis and human papilloma virus. She received her M.P.H. from the University of South Florida in Tampa.
Nishant Kumar, M.P.H., is a senior director on the Epidemiology team at Clarivate. His areas of expertise are oncology and CNS diseases, including Alzheimer’s disease and dementia. His key interests in oncology are modeling disease progression and drug-treatable incident and prevalent populations. Previously, Mr. Kumar sized patient populations for rare and niche diseases, such as graft-versus-host disease and Duchenne muscular dystrophy. He earned his M.P.H. with a concentration in epidemiology and statistics from King’s College in London and a B.Sc. (Honors) in medical studies from the University of Birmingham.